GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Curis, Inc. (CRIS) [hlAlert]

Rating:
Mkt Outperform
CRIS
up 90.83 %

Curis, Inc. (CRIS) rated Mkt Outperform with price target $3 by Rodman & Renshaw

Posted on: Thursday,  May 15, 2008  11:25 AM ET by Rodman & Renshaw

Rodman & Renshaw rated Mkt Outperform Curis, Inc. (NASDAQ: CRIS) on 05/15/2008, when the stock price was $1.31.
Since then, Curis, Inc. has gained 90.84% as of 01/22/2016's recent price of $2.50.
If you would have followed this Rodman & Renshaw's recommendation on CRIS, you would have gained 90.83% of your investment in 2808 days.

Curis, Inc. is a therapeutic drug development company focusing on cancer, neurological and dermatological disease indications, with technologies that utilize regulatory pathways that control repair and regeneration. Curis' product development involves the use of small molecules or proteins to modulate these pathways. The company has successfully used this technology and product development approach to produce several promising drug product candidates in the fields of cancer, neurological disorders, hair growth, kidney and other diseases, as well as cardiovascular disease.

Rodman & Renshaw is a full-service investment bank dedicated to providing investment banking services to companies that have significant recurring capital needs due to their growth and development strategies. We also provide research and sales and trading services to institutional investor clients that focus on such companies. Since 2003, Rodman has been a leading investment banking firm to the biotechnology sector, a capital intensive market segment, as well as a leader in the PIPE (private investment in public equity) and RD (registered direct placements) transaction markets.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
5/15/2008 11:25 AM Buy
None
1.31 3.00
as of 12/24/2008
1 Week up  3.81 %
1 Month up  13.33 %
3 Months up  58.13 %
1 YTD up  81.33 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy